D R Horton Inc vs Mesoblast Limited — how do they compare? D R Horton Inc trades at $146.16 (market cap $42.18B), while Mesoblast Limited trades at $16.98 (market cap $2.21B). The key difference: D R Horton Inc is far larger — about 19.1× Mesoblast Limited's market cap, and D R Horton Inc pays a 1.19% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| DHI | MESO | |
|---|---|---|
Market Cap | $42.18B | $2.21B |
Sector | Consumer Cyclical | Technology |
52-Week High | $184.04 | $20.96 |
52-Week Low | $132.53 | $12.88 |
Enterprise Value | $47.28B | $2.21B |
Dividend Yield | 1.19% | — |
Signals from Pluang's Aura AI — not financial advice
DHI trades at $146.66, down 2.93% on the day, amid a bearish technical signal. The stock has consistently beaten earnings estimates in recent quarters, including Q2 2026 EPS of $3.20 versus $3.02 expected. However, revenue and net income have trended lower from 2023 peaks, with 2025 revenue at $34.25B and net income at $3.59B. The company maintains a reasonable valuation with a P/E of 14.37 and recently declared a $0.45 dividend payable in August 2026.
The outlook is mixed; strong execution and cash returns support the stock, but lowered guidance and margin pressure from elevated mortgage rates pose headwinds. Analyst consensus is nearly evenly split between Buy and Hold, with a $153 price target suggesting modest upside. Key risks include persistent demand softness in housing and competitive disruption from new entrants like Boxabl.
No Aura AI signal available yet.
Trailing returns across standard periods
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →